| __timestamp | Bausch Health Companies Inc. | Madrigal Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2026300000 | 15746000 |
| Thursday, January 1, 2015 | 2682700000 | 13392000 |
| Friday, January 1, 2016 | 2810000000 | 9290000 |
| Sunday, January 1, 2017 | 2582000000 | 7672000 |
| Monday, January 1, 2018 | 2473000000 | 15293000 |
| Tuesday, January 1, 2019 | 2554000000 | 22648000 |
| Wednesday, January 1, 2020 | 2367000000 | 21864000 |
| Friday, January 1, 2021 | 2624000000 | 37318000 |
| Saturday, January 1, 2022 | 2625000000 | 48130000 |
| Sunday, January 1, 2023 | 2917000000 | 108146000 |
Data in motion
In the competitive landscape of pharmaceuticals, understanding the financial strategies of industry players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Madrigal Pharmaceuticals, Inc. and Bausch Health Companies Inc. over the past decade.
From 2014 to 2023, Bausch Health consistently allocated a significant portion of its budget to SG&A expenses, peaking in 2023 with a 44% increase from 2014. This reflects a strategic focus on maintaining market presence and operational efficiency. In contrast, Madrigal Pharmaceuticals, Inc. exhibited a dramatic rise in SG&A expenses, surging by over 580% during the same period. This suggests an aggressive expansion strategy, likely aimed at scaling operations and enhancing market penetration.
These trends highlight the diverse approaches companies take in managing operational costs, offering insights into their strategic priorities and market positioning.
Who Optimizes SG&A Costs Better? Novo Nordisk A/S or Bausch Health Companies Inc.
Breaking Down SG&A Expenses: argenx SE vs Madrigal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Halozyme Therapeutics, Inc. vs Bausch Health Companies Inc.
Blueprint Medicines Corporation and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs Opthea Limited Trends and Insights
Selling, General, and Administrative Costs: Madrigal Pharmaceuticals, Inc. vs Verona Pharma plc
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Viking Therapeutics, Inc.
Madrigal Pharmaceuticals, Inc. or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?
Corcept Therapeutics Incorporated vs Bausch Health Companies Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Bausch Health Companies Inc. vs ImmunityBio, Inc.
Comparing SG&A Expenses: Bausch Health Companies Inc. vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Bausch Health Companies Inc. and Celldex Therapeutics, Inc.: SG&A Spending Patterns Compared